Trial Profile

The phase 1 study of HXN-1001 in healthy volunteers.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HXN 1001 (Primary)
Indications Inflammatory bowel diseases; Psoriasis
Focus Adverse reactions

Most Recent Events

22 Jul 2025 New trial record
10 Jul 2025 According to Earendil Labs media release, it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com